Antiemetic action of 5-HT3 receptor antagonists: review of preclinical and clinical results with ICS 205-930.
These results thus indicate, that ICS 205-930 is a very effective antiemetic for cancer chemotherapy-induced emesis in man. Given as a single dose prior to the chemotherapeutic agent, ICS 205-930 inhibits emesis and nausea for at least 24 hr. Together with the lack of extrapyramidal side-effects, these properties of ICS 205-930 indicate a clear superiority to the current therapeutic standard metoclopramide.
Gamse
R
R
Preclinical Research, Sandoz Pharma Ltd, Basle, Switzerland.
D000818:Animals; D000932:Antiemetics / Q000737:chemistry / Q000627:therapeutic use*; D002415:Cats; D002945:Cisplatin / Q000009:adverse effects; D004285:Dogs; D004341:Drug Evaluation; D005289:Ferrets; D006801:Humans; D007211:Indoles / Q000737:chemistry / Q000627:therapeutic use*; D009325:Nausea / Q000139:chemically induced / Q000188:drug therapy; D012702:Serotonin Antagonists / Q000737:chemistry / Q000627:therapeutic use*; D000077526:Tropisetron; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
D000932:Antiemetics; D007211:Indoles; D012702:Serotonin Antagonists; D000077526:Tropisetron; D002945:Cisplatin